Imbria Pharmaceuticals to Participate in the UBS Biotechnology Private Company Virtual Symposium
September 15, 2022 08:00 ET
|
Imbria Pharmaceuticals Inc.
BOSTON, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022
September 12, 2022 08:00 ET
|
Enlivex Therapeutics Ltd
Currently used cisplatin-based combination treatments have limited efficacy against mesothelioma, which is one of the deadliest solid cancers Combining cisplatin with Allocetra™ led to a...
Processa Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 12-14, 2022
September 07, 2022 08:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality...
Medigus: Polyrizon Signed an Agreement with Nurexone for Intranasal Administration of Cutting - Edge Therapy for Spinal Cord Injuries
July 18, 2022 08:00 ET
|
Medigus Ltd
Polyrizon will be entitled for up to $3.35 million in addition to future royalties Tel Aviv, Israel, July 18, 2022 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged...
Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ
May 19, 2022 09:15 ET
|
Adhera Therapeutics, Inc.
Baton Rouge, LA, May 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the...
QSAM Biosciences Receives Japanese Patent for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®
April 12, 2022 08:00 ET
|
QSAM Biosciences Inc.
Austin, TX, April 12, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
Wayne A. Marasco, M.D., Ph.D. joins Invectys’ Scientific Advisory Board
March 09, 2022 10:00 ET
|
Invectys, Inc.
Houston, Texas, USA, March 09, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. of Houston, Texas, a clinical stage immunotherapy company dedicated to the development of a next generation of therapies to...
Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace
January 20, 2022 08:45 ET
|
Adhera Therapeutics, Inc.
Baton Rouge, LA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce its...
Adhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of Directors
November 08, 2021 09:15 ET
|
Adhera Therapeutics, Inc.
Baton Rouge, LA, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the...
Adhera Receives European Patent Covering MLR-1019 and Derivatives for Treating Dyskinesias
October 04, 2021 09:15 ET
|
Adhera Therapeutics, Inc.
Baton Rouge, LA, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new...